As originally conceived, personalized medicine referred to the tailoring of medical treatment to the individual characteristics of each patient. The right drug for the right patient at the right timehas since evolved to an approach that takes into account individual differences in people’s genes, environments, and lifestyles.
While most large pharma companies seem “very open” to new technologies, a recent FiercePharma article also notes that the life science industry hasn’t exactly won accolades for its speed in adopting new artificial intelligence and machine learning technologies. However, since patient lives are at stake, the industry has good reason to proceed with caution.*
Dena Raffa, Director, Account Operations and BBK’s expert in digital innovation, shares her view on the complex topic of AI and machine learning technologies in life sciences.
A recent survey shared in FiercePharma pointed to an upward trend in general public opinion of the pharmaceutical industry. But there is still work to be done.*
Rob Laurens, Principal, Human Resources and Quality Assurance, credits much of this momentum to the work of everyone in the clinical R&D sector.
Last year, smaller companies led in new drug approvals, according to a recent OutsourcingPharma.com article featuring Ken Getz, director of sponsored research at Tufts University. Notably, nearly half of these new drugs were for the treatment of rare diseases, demonstrating a shift within the industry away from a focus on scaling infrastructure.*
CEO and Founding Principal of BBK Worldwide, Joan F. Bachenheimer, responds to the article, explaining that “the precision aspects of clinical trial discovery have remapped the patient experience. The more targeted the investigational therapy, the more individualized the orientation becomes toward patient recruitment and engagement. It’s logical that the search for patients with specific biomarkers begets an orientation centered on individual needs versus a mass orientation."
BBK’s RSG® Arrive patient travel program continues to stand out in an increasingly crowded marketplace of companies offering concierge travel and ride-hailing services. One of the reasons RSG® Arrive is in a class by itself is the dedication, commitment to care, and professionalism of its drivers. They routinely go above and beyond to ensure the comfort and care of their passengers.
To recognize the important role that our RSG® Arrive drivers play in enhancing the clinical trial patient experience, we will be celebrating a driver of the month, starting this month with Viken.
Season 2 Episode 2: As part of our Pharma15 Live! web series, we recently had the opportunity to sit down with three-time clinical trial participant Richard Brescia for a candid conversation about his experience – both positive and negative. As an industry, we can learn a tremendous amount by going directly to the heart of the matter and listening to the “patient voice.”
When examining the clinical trial experience, there’s nothing more meaningful than hearing directly from those closest to the study – patients, caregivers, physicians, and study sponsors. This year BBK launched its Study Voices initiative. Study Voices is designed to capture the sentiment of the study community at a time when the clinical research industry is growing and evolving. From innovative technology, to protocol design, and everything in between, Study Voices captures the perspectives of those closest to the clinical trial experience, offering insight that can be leveraged for action.
“Focus 5: Amplifying the Study Voice” highlights five members of the study community as they share their perspectives on the clinical trial experience.
In a world where communications, content, and news constantly need to be bigger, better and brighter than what came before, getting your clinical trial noticed outside of the physician’s office can be a challenge. Strict rules and regulations for advertising campaigns can make it hard to make an impact among today’s sensationalized media backdrop. How do you stand out from the crowd? It’s easier than you think if you know what to look for, and how to capitalize on opportunities.
Patient engagement is important, but so is the engagement of doctors and medical personal delivering the protocol to the patient. Gerald Wayne Dryden, Jr., MD, PhD from the University of Louisville discusses patient engagement in a special edition of Pharma 15 Live! with fellow panelists Linda A. Glaser, MD, PhD from Coastal Biomedical Research, Inc. and Annie Finstein, a clinical trial participant.